These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 6729219)

  • 21. Complete remission with combination chemotherapy in metastatic breast carcinoma.
    Polyzos A; Buzdar AU
    Am J Clin Oncol; 1986 Aug; 9(4):361-3. PubMed ID: 3751975
    [No Abstract]   [Full Text] [Related]  

  • 22. Postmenopausal breast cancer: is the short-term pain worth the long-term gain?
    Pritchard KI
    Lancet; 1996 Apr; 347(9008):1057-8. PubMed ID: 8602051
    [No Abstract]   [Full Text] [Related]  

  • 23. Cyclical use of tamoxifen and high-dose medroxyprogesterone acetate in advanced estrogen receptor positive breast cancer.
    Gundersen S; Kvinnsland S; Lundgren S; Klepp O; Lund E; Børmer O; Høst H
    Breast Cancer Res Treat; 1990 Nov; 17(1):45-50. PubMed ID: 2151369
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rational approaches to the hormonal treatment of breast cancer.
    Allegra JC
    Semin Oncol; 1983 Dec; 10(4 Suppl 4):25-8. PubMed ID: 6669986
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship between estrogen receptors and CMF adjuvant chemotherapy.
    Bonadonna G; Di Fronzo G; Tancini G; Brambilla C; Rossi A; Marchini S; Valagussa P
    Recent Results Cancer Res; 1984; 91():205-9. PubMed ID: 6547243
    [No Abstract]   [Full Text] [Related]  

  • 26. Adjuvant systemic therapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group's trials of cyclophosphamide or CMF in premenopausal and tamoxifen in postmenopausal patients.
    Mouridsen HT; Rose C; Brincker H; Thorpe SM; Rank F; Fischerman K; Andersen KW
    Recent Results Cancer Res; 1984; 96():117-28. PubMed ID: 6396765
    [No Abstract]   [Full Text] [Related]  

  • 27. Value of hormone receptors in the management of breast cancer--I. Advanced breast cancer.
    Cant EM; Horsfall D; Keightley DD
    Aust N Z J Surg; 1985 Apr; 55(2):121-5. PubMed ID: 3862384
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The management of advanced breast cancer.
    Baum M
    Br J Hosp Med; 1980 Jan; 23(1):32, 35, 37-9. PubMed ID: 6153539
    [No Abstract]   [Full Text] [Related]  

  • 29. [New data on relations between residual hormonal modulability and medical treatment of breast adenocarcinoma].
    Prodi G; Lollini PL; Nicoletti G
    Minerva Med; 1984 Feb; 75(6):219-21. PubMed ID: 6709205
    [No Abstract]   [Full Text] [Related]  

  • 30. The role of progestins and progesterone receptors in the treatment of breast cancer.
    Sedlacek SM; Horwitz KB
    Steroids; 1984 Dec; 44(6):467-84. PubMed ID: 6400150
    [No Abstract]   [Full Text] [Related]  

  • 31. Combined modality therapy for first recurrence of breast cancer. A Southwest Oncology Group study.
    Hoogstraten B; Gad-el-Mawla N; Maloney TR; Fletcher WS; Vaughn CB; Tranum BL; Athens JW; Costanzi JJ; Foulkes M
    Cancer; 1984 Nov; 54(10):2248-56. PubMed ID: 6488144
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Re: Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer.
    Atkins CD
    J Natl Cancer Inst; 1998 Mar; 90(6):468-9. PubMed ID: 9521174
    [No Abstract]   [Full Text] [Related]  

  • 33. Tamoxifen therapy in premenopausal women with metastatic breast cancer.
    Planting AS; Alexieva-Figusch J; Blonk-vdWijst J; van Putten WL
    Cancer Treat Rep; 1985 Apr; 69(4):363-8. PubMed ID: 3995508
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent developments in the endocrine treatment of breast cancer.
    Stoll BA
    Eur J Cancer (1965); 1980; Suppl 1():79-80. PubMed ID: 7318874
    [No Abstract]   [Full Text] [Related]  

  • 35. Consensus: use of estrogen receptor assay.
    Check WA
    JAMA; 1979 Oct; 242(16):1714-6. PubMed ID: 480590
    [No Abstract]   [Full Text] [Related]  

  • 36. Principles and indications of endocrine treatment of advanced breast cancer.
    Mouridsen HT; Palshof T
    Recent Results Cancer Res; 1980; 71():112-7. PubMed ID: 7367722
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systemic adjuvant therapy for node-negative breast cancer: proven or premature?
    Pritchard KI
    Ann Intern Med; 1989 Jul; 111(1):1-4. PubMed ID: 2660644
    [No Abstract]   [Full Text] [Related]  

  • 38. A randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer.
    Lipton A; Harvey HA; Santen RJ; Boucher A; White D; Bernath A; Dixon R; Richards G; Shafik A
    Cancer; 1982 Dec; 50(11):2265-8. PubMed ID: 6754061
    [No Abstract]   [Full Text] [Related]  

  • 39. Estrogen receptors in breast cancer--therapeutic response to the treatment of recurrences.
    Pinotti JA; Teixeira LC; Pisani RC; Bastos SR
    Int J Gynaecol Obstet; 1987 Apr; 25(2):127-31. PubMed ID: 2884137
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ovarian ablation as adjuvant therapy for breast cancer.
    Davidson NE
    J Natl Cancer Inst Monogr; 2001; (30):67-71. PubMed ID: 11773295
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.